Shots:

• F-star to receive option exercise payment and will be eligible to get milestones and royalties on net sales of therapies resulting from the collaboration
• Merck KGaA exercises its third option to develop an additional bispecific program under the ongoing collaboration with F-star
• Merck KGaA will be responsible for the development and commercialization of the preclinical program. In 2019- the companies collaborated with the first option to license while in July’2020- Merck KGaA brought the second program from the collaboration into its pipeline

  Ref: GlobeNewswire | Image: Merck KGaA